BZ371A
Phase 2Small molecule
BZ371A is one of 94 small molecule programs targeting Efficacy. It is currently in Phase 2.
2
Indications
4
Total Trials
3
Active Trials
93
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
149 competitors in Safety and Efficacy
#DrugCompanyPhaseTrials
1Rituxan
RochePhase 3
Opdivo
Bristol-Myers SquibbPhase 3
Humira
NovartisPhase 3
Avastin
RochePhase 3
Adriamycin
PfizerPhase 3
Oncovin
Eli LillyPhase 3
BEYFORTUS
SanofiPhase 3
Neulasta
AmgenPhase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Rayos
RRoxane Laboratories
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Efficacy2 trials
Safety and Efficacy1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BZ371A. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- BBiozeus Biopharmaceutical S.A.